IP Library Granted Patent US 9,949,936
Granted Patent B2
US 9,949,936 · App. 15/284,766 · Granted Apr 24, 2018

Use of cannabinoids in the treatment of epilepsy

Inventors: Geoffrey Guy (Cambridge, GB); Stephen Wright (Cambridge, GB); Alice Mead (Cambridge, GB); Charuta Joshi (Iowa City, IA); Angus Wilfong (Houston, TX)
Assignee: GW Pharma Limited
A61K31/05A61K9/0053A61K9/08A61K31/19A61K31/27A61K31/4015A61K31/4166A61K31/444A61K31/515A61K31/53A61K31/55A61K31/551A61K36/185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,936
App. No.
15/284,766
Filed
Oct 4, 2016
Granted
Apr 24, 2018
Kind
B2
Art Unit
1626
USPC
514/94
Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Claims (14)

1. A method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a subject in need thereof, wherein the epilepsy is status epilepticus due to febrile infection related epilepsy syndrome (FIRES).

2. The method of claim 1 , wherein the CBD is administered in combination with two or more concomitant anti-epileptic drugs (AED).

3. The method of claim 2 , wherein the seizure type to be treated is a complex partial seizure (focal seizure with impairment).

4. The method of claim 2 , wherein the CBD is administered in an amount that reduces total convulsive seizure frequency by greater than 70% with respect to the seizure frequency achieved on the concomitant anti-epileptic drugs (AED).

5. The method of claim 2 , wherein the CBD is administered in an amount that reduces total convulsive seizure frequency by greater than 90% with respect to the seizure frequency achieved on the concomitant anti-epileptic drugs (AED).

6. The method of claim 2 , wherein the CBD is administered in an amount that reduces total convulsive seizure frequency by 100% with respect to the seizure frequency achieved on the concomitant anti-epileptic drugs (AED).

7. The method of claim 1 , wherein the CBD is a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.

8. The method of claim 2 , wherein the two or more concomitant anti-epileptic drugs (AED) are administered in combination with the CBD at a dose that is reduced from a recommended therapeutic dose without CBD.

9. The method of claim 8 , wherein the dose of AED which is reduced is of clobazam.

10. The method of claim 1 , wherein the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.

11. The method of claim 1 , wherein the dose of the CBD is at least 5 mg/kg/day.

12. The method of claim 1 , wherein the dose of the CBD is at least 10 mg/kg/day.

13. The method of claim 1 , wherein the dose of the CBD is at least 15 mg/kg/day.

14. The method of claim 1 , wherein the dose of the CBD is at least 20 mg/kg/day.

Assignments (4)
CHANGE OF NAME Recorded May 16, 2024
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 067437/0875 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSET PURCHASE BY WAY OF DEED Recorded Oct 4, 2018
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 047192/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2017
From: GUY, GEOFFREY; WRIGHT, STEPHEN; MEAD, ALICE; JOSHI, CHARUTA; WILFONG, ANGUS
To: GW PHARMA LIMITED
Reel/Frame 041985/0180 →
Priority Claims (2)
GB 1410771.8 · Jun 17, 2014 · national
GB 1506550.1 · Apr 17, 2015 · national
Continuity (2)
Continuation 14741783 · Jun 17, 2015
Related Publication 20170246121A1 · Aug 31, 2017